-
Research and Reports in Urology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle
Review
(2133) Views (573) Full article downloads
Authors: Alfredo Berruti, Francesca Vignani, Lucianna Russo, et al
Published Date July 2010
Volume 2010:2 Pages 109 - 124
DOI: http://dx.doi.org/10.2147/RRU.S6573
Alfredo Berruti1, Francesca Vignani1, Lucianna Russo1, Valentina Bertaglia1, Mattia Tullio1, Marcello Tucci1, Massimiliano Poggio2, Luigi Dogliotti11Oncologia Medica, 2Urologia, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Azienda Ospedaliero Universitaria San Luigi, Orbassano, Italy
Abstract: Neuroendocrine (NE) differentiation is a common feature in prostate cancer (PC). The clinical significance of this phenomenon is controversial; however preclinical and clinical data are in favor of an association with poor prognosis and early onset of a castrate resistant status. NE PC cells do not proliferate, but they can stimulate the proliferation of the exocrine component through the production of paracrine growth factors. The same paracrine signals may favor the outgrowth of castrate adapted tumors through androgen receptor dependent or independent mechanisms. Noteworthy, NE differentiation in PC is not a stable phenotype, being stimulated by several agents including androgen deprivation therapy, radiation therapy, and chemotherapy. The proportion of NE positive PC, therefore, is destined to increase during the natural history of the disease. This may complicate the assessment of the prognostic significance of this phenomenon. The majority of clinical studies have shown a significant correlation between NE differentiation and disease prognosis, confirming the preclinical rationale. In conclusion the NE phenotype is a prognostic parameter in PC. Whether this phenomenon is a pure prognostic factor or whether it can influence the prognosis by favoring the onset of a castrate resistance status is a matter of future research.
Keywords: prostate cancer, prognosis, neuroendocrine differentiation
Readers of this article also read:
Oxybutynin topical gel in the treatment of overactive bladder
Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
Update on vaccine development for renal cell cancer
Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy
Ferritin light chain and squamous cell carcinoma antigen 1 are coreceptors for cellular attachment and entry of hepatitis B virus
A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients
Corrigendum
Transient elastography with the XL probe rapidly identifies patients with nonhepatic ascites
Corrigendum
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Distal femoral opening-wedge osteotomy for lateral compartment osteoarthritis of the knee
- Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
- Neurotransmitter testing of the urine: a comprehensive analysis
- Ipsilateral pedicle screw placement with contralateral percutaneous facet screws: Early results with an alternative in lumbar arthrodesis




